Human FGF-BP Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB1593

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
MAB1593
MAB1593-SP
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Western Blot

Cited:

ELISA Capture, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 196519

View all FGF-BP Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human FGF-BP
Val35-Cys234
Accession # Q14512

Specificity

Detects human FGF-BP in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant rat FGF-BP is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human FGF-BP Antibody

Detection of Human FGF-BP by Western Blot

Detection of Human FGF-BP by Western Blot

miR-217 targets KLF5 by binding to its 3’UTR.A. miR-217 decreased the KLF5, FGF-BP and Cyclin D1 protein levels in HCC1806 and HCC1937 TNBC cells. KLF5, FGF-BP and Cyclin D1 protein levels were detected by using WB. beta-actin was used as the loading control. B. The putative wild type binding sites of miR-217 on KLF5 3’UTR and its mutants. C. miR-217 mimics significantly inhibits the KLF5 3’UTR luciferase reporter activity through the second putative binding site. HEK293T cells were transfected with miR-217 mimics and pMIR-KLF5 3’-UTR or miR-217 binding sites mutated pMIR-KLF5 3’-UTR reporters (mut1, mut2 or mut1,2) together with the pCMV-Renilla control. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0176395), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human FGF-BP Antibody

Application
Recommended Usage

Western Blot

1 µg/mL
Sample: Recombinant Human FGF-BP (Catalog # 1593-FB)

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FGF-BP

Fibroblast growth factor binding protein (FGF‑BP), also known as HBp17, is a secreted glycoprotein that increases the bioavailability of FGFs (1). Mature FGF-BP is a 34 kDa, 211 amino acid (aa) O-glycosylated protein with five conserved intrachain disulfide bonds (2‑4). FGF-BP contains a heparin-binding domain (aa 110‑143) and a distinct FGF-binding region (aa 193‑243) (5). Mature human FGF‑BP shares 59% and 54% aa sequence identity with mouse and rat FGF-BP, respectively. FGF-BP is expressed throughout development and in adult squamous epithelium (2, 6). It is upregulated in injured skin, renal tubular epithelium, and spinal nerves as well as in carcinomas of the skin, colon, and pancreas (3, 7‑10). FGF-BP binds FGF-1, -2, -7, -10, and -22 which are secreted and sequestered in the extracellular matrix (ECM) (7, 11). The association of FGF-BP with heparan sulfate proteoglycans (HSPG) weakens HSPG attachment of FGFs and promotes their release (2, 8, 12, 13). FGF‑BP enhances the mitogenic effects of FGFs, thereby contributing to epithelial, endothelial, and neuronal tissue repair, angiogenesis, and tumor growth (7‑9, 11, 14, 15).

References

  1. Abuharbeid, S. et al. (2006) Int. J. Biochem. Cell Biol. 38:1463.
  2. Wu, D. et al. (1991) J. Biol. Chem. 266:16778.
  3. Tassi, E. et al. (2006) Cancer Res. 66:1191.
  4. Lametsch, R. et al. (2000) J. Biol. Chem. 275:19469.
  5. Xie, B. et al. (2006) J. Biol. Chem. 281:1137.
  6. Aigner, A. et al. (2002) Histochem. Cell Biol. 117:1.
  7. Beer, H-D. et al. (2005) Oncogene 24:5269.
  8. Ray, P.E. et al. (2006) Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:R105.
  9. Tassi, E. et al. (2007) Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R775.
  10. Kurtz, A. et al. (2004) Neoplasia 6:595.
  11. Tassi, E. et al. (2001) J. Biol. Chem. 276:40247.
  12. Mongiat, M. et al. (2001) J. Biol. Chem. 276:10263.
  13. Kurtz, A. et al. (1997) Oncogene 14:2671.
  14. Aigner, A. et al. (2001) Int. J. Cancer 92:510.
  15. Czubayko, F. et al. (1997) Nat. Med. 3:1137.

Long Name

Fibroblast Growth Factor Binding Protein

Alternate Names

FGF-BP1, FGFBP, FGFBP-1, FGFBP1, HBp17

Entrez Gene IDs

9982 (Human); 14181 (Mouse); 64535 (Rat)

Gene Symbol

FGFBP1

UniProt

Q14512

Additional FGF-BP Products

Product Documents for Human FGF-BP Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human FGF-BP Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.